Asian Journal of Pharmaceutical Research and Health Care, published by Wolters Kluwer Medknow Publications, serves as a vital platform for disseminating cutting-edge research in the fields of pharmacology, toxicology, and healthcare. With an ISSN of 2250-1444 and an E-ISSN of 2250-1460, this journal aims to provide valuable insights and advancements in pharmaceutical sciences, targeting researchers, practitioners, and students dedicated to improving health outcomes. Although its coverage in Scopus was discontinued in 2016, the journal maintains importance within the academic community by fostering discourse and sharing knowledge on emerging topics. Despite its challenges reflected in the low Scopus ranking within its category, the Asian Journal of Pharmaceutical Research and Health Care remains committed to enhancing access to critical research and publishing high-quality work that bridges the gap between theory and practice in health care. Researchers and professionals engaged in the pharmaceutical field are encouraged to contribute and leverage this journal as a means to advance their work and elevate healthcare standards in Asia and beyond.

Current Reviews in Clinical and Experimental Pharmacology is a cutting-edge journal published by Bentham Science Publishers in the United Arab Emirates, focusing on the dynamic field of pharmacology. With an ISSN of 2772-4328 and an E-ISSN of 2772-4336, this journal has rapidly established itself as a significant resource for researchers and professionals in the medical and pharmaceutical sciences since its inception in 2021. It boasts an impressive Q3 ranking in Pharmacology (medical) and Q2 in the Pharmacology, Toxicology and Pharmaceutics (miscellaneous) category as of 2023. Furthermore, it ranks #14/80 in general pharmacology, reflecting its esteemed position within the scientific community. As an Open Access publication, it ensures that groundbreaking research is readily accessible, fostering collaboration and innovation. The journal invites high-quality reviews and original articles that address contemporary issues and advancements in clinical and experimental pharmacology, making it an essential venue for disseminating knowledge and engaging with emerging trends in therapeutic developments.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, an esteemed publication in the field of pharmacology, is published by Wiley-Hindawi and has been at the forefront of clinical research since its inception in 1976. Operating primarily from the United Kingdom, this journal features a diverse array of articles that encompass both fundamental and practical aspects of clinical pharmacy, thereby supporting the advancement of therapeutic practices. With an ISSN of 0269-4727 and an E-ISSN of 1365-2710, it is indexed in key databases and holds respectable ranks within its categories; achieving Q3 in Pharmacology and Q2 in Medical Pharmacology in the latest quartile rankings. Its Scopus ranking reflects both its quality and relevance, being positioned in the 55th percentile for medical pharmacology and the 45th for pharmacology, toxicology, and pharmaceutics. Although it does not currently operate under an Open Access model, the journal's extensive readership and rigorous peer-review process ensure that the latest research reaches practitioners and academics alike. With a commitment to bridging the gap between pharmacological science and clinical practice, the JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS remains a critical resource for professionals striving to enhance patient outcomes through informed medication management.

The JOURNAL OF DERMATOLOGICAL TREATMENT, published by TAYLOR & FRANCIS LTD, is a premier forum dedicated to advancing the field of dermatology through the dissemination of high-quality research. Since its inception in 1989, this journal has maintained a significant impact on the dermatological community, currently ranking in the top quartile (Q1) of the Dermatology category with an impressive Scopus ranking of #14 out of 142 journals, reflecting its reputation among peers and its contribution to the clinical and academic landscape. The journal shifted to Open Access in 2023, enhancing the accessibility of groundbreaking findings to researchers, clinicians, and students worldwide. With a commitment to publishing diverse articles, from innovative treatment modalities to comprehensive reviews, the JOURNAL OF DERMATOLOGICAL TREATMENT serves as an invaluable resource for professionals seeking to stay at the forefront of dermatological science in a rapidly evolving field.

Drug Healthcare and Patient Safety is a premier Open Access journal, published by DOVE MEDICAL PRESS LTD since 2009, dedicated to advancing the understanding and practices surrounding medication safety and healthcare delivery. With its ISSN 1179-1365 and E-ISSN matching, this New Zealand-based journal not only fosters global discourse but also prioritizes the dissemination of research that intersects both health policy and pharmacology. Categorized as Q2 in Health Policy and Q3 in Pharmacology for the year 2023, it occupies a notable position within the academic community, as reflected by its Scopus rankings, which place it in the 66th and 45th percentiles of its respective categories. Drug Healthcare and Patient Safety aims to provide a platform for researchers, practitioners, and students to share innovative findings, promote safe medication practices, and explore the implications of health policy on patient outcomes. As an Open Access journal, it ensures that vital research is accessible to a wider audience, making significant contributions to the ongoing dialogue in the fields of healthcare and pharmacovigilance.

Cancer Treatment Reviews, published by Elsevier Science Ltd, is a leading international journal dedicated to the exploration and advancement of therapeutic strategies in oncology. With an impressive impact factor that reflects its status in the field, this journal is classified within Q1 quartile rankings in Medicine (Miscellaneous), Oncology, and Radiology, Nuclear Medicine and Imaging, as of 2023. The journal has a rich lineage, having been established in 1974 and consistently evolving to encompass the latest breakthroughs and methodologies in cancer treatment. A vital resource for researchers, clinicians, and students alike, it aims to promote understanding and application of effective interventions, thereby contributing to improvements in patient outcomes. By prioritizing high-quality reviews, Cancer Treatment Reviews plays an essential role in bridging the gap between current research and clinical practice, making it an indispensable asset in the continuous fight against cancer.

The American Journal of the Medical Sciences, published by Elsevier Science Inc, has been a cornerstone in the field of medicine since its inception in 1945. With ISSN 0002-9629 and E-ISSN 1538-2990, this esteemed journal provides a comprehensive forum for the dissemination of cutting-edge research and clinical advancements across various medical disciplines. It currently holds a distinguished Q2 ranking in the field of Medicine (miscellaneous) and ranks #118 out of 636 in General Medicine on Scopus, reflecting its significant impact with an 81st percentile rating. While it operates under a traditional publishing model, which ensures rigorous peer-review processes, its commitment to disseminating vital medical knowledge remains paramount. Based in the United States at STE 800, 230 Park Ave, New York, NY 10169, the journal aims to bridge the gap between research and practice, making it an invaluable resource for researchers, healthcare professionals, and students dedicated to advancing medical science and improving patient care.

Current Drug Safety is a distinguished peer-reviewed journal published by Bentham Science Publishers, focusing on the critical intersection of pharmacology and toxicology. With an ISSN of 1574-8863 and an E-ISSN of 2212-3911, this journal serves as a platform for the latest research and advances in drug safety, highlighting the importance of pharmacological assessments and toxicity evaluations in therapeutic development and public health. Reaching a broad international audience from its base in the United Arab Emirates, Current Drug Safety offers an invaluable resource for researchers, professionals, and students interested in the dynamic fields of drug research and safety management. Despite a current Q3 categorization in multiple pharmacology and toxicology quartiles for 2023, the journal continues to strive for excellence in the scholarly community, reflecting its commitment to disseminating high-quality research. While not operating under an open access model, articles can be accessed through institutional subscriptions and other platforms, ensuring valuable insights into drug safety are available to those who need it most.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE is a premier peer-reviewed academic journal published by WILEY-HINDAWI, dedicated to advancing the field of clinical medicine. With an ISSN of 1368-5031 and E-ISSN 1742-1241, this open access journal has been providing a platform for insightful research since its inception in 1997 and continues to contribute significantly to the medical community, as indicated by its Q2 ranking in Medicine (miscellaneous) for 2023 and its position in the top 15% of Scopus-ranked journals. The journal invites innovative studies, systematic reviews, and clinical trials, making it a critical resource for healthcare professionals, researchers, and students seeking to stay updated on the latest clinical practices. Based in the United Kingdom at Adam House, 3rd Fl, 1 Fitzroy Sq, London W1T 5HE, this journal supports open accessibility, enhancing the dissemination of vital research findings across the globe. Join the growing community of scholars who contribute to and benefit from this influential publication as it continues to shape the future of clinical practice.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, published by DUSTRI-VERLAG DR KARL FEISTLE in Germany, is a vital scholarly platform dedicated to advancing the field of pharmacology through rigorous research and innovative therapeutic strategies. Established in 1994, this journal has maintained its relevance in the evolving landscape of clinical pharmacology, achieving a Q3 rank in both general and medical pharmacology categories as of 2023. With an ISSN of 0946-1965, it is positioned as an essential resource for researchers, healthcare professionals, and students seeking to enhance their understanding of drug therapy and pharmacological applications. Though it currently does not offer open access, its comprehensive scope covers a wide array of topics within pharmacology, promising to contribute significantly to scientific discussions and knowledge dissemination from 1994 to 2024. Whether you are looking for the latest studies or historical insights, the journal remains a fixture for anyone invested in the pharmacological sciences.